Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL709199

O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.c1ccc(COc2ccc(-c3nc4cccnc4[nH]3)c(OCc3ccccn3)c2)cc1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.43
GPR132 Q9UNW8 1/20 0.40
MAPK14 Q16539 2/20 0.40
SMO Q99835 2/20 0.40
SYK P43405 2/20 0.40
KMT2A Q03164 2/20 0.39
PDE5A O76074 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
CYP3A4 P08684 1/20 0.39
CSNK2A2 P19784 1/20 0.39
CSNK2A1 P68400 1/20 0.39
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
APP P05067 1/20 0.38
MAPT P10636 1/20 0.38
DHODH Q02127 1/20 0.38
CYP11B1 P15538 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL711971 0.95 CYP3A4 (0.43) PDE5APDE4APDE4BPDE4CPDE4D
Trifluoroacetic Acid SCHEMBL713332 0.93 KMT2A (0.41) PTPN1GPR132MAPK14SMOSYK
SCHEMBL10206654 0.92 SYK (0.46) PTPN1MAPK14SMOSYKKMT2A
Trifluoroacetic Acid SCHEMBL711513 0.88 SMO (0.41) GPR132MAPK14SMOSYKCSNK2A2
Trifluoroacetic Acid SCHEMBL711226 0.88 SMO (0.41) PTPN1SMOPDE5APDE4APDE4B
Trifluoroacetic Acid SCHEMBL709554 0.87 CYP3A4 (0.43) GPR132PDE5APDE4APDE4BPDE4C
Trifluoroacetic Acid SCHEMBL713321 0.87 FFAR1 (0.41) KMT2APDE5APDE4APDE4BPDE4C
Trifluoroacetic Acid SCHEMBL711286 0.86 PDE5A (0.41) PDE5APDE4APDE4BPDE4CPDE4D
Trifluoroacetic Acid SCHEMBL711950 0.86 CYP3A4 (0.39) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL9071887 0.86 CYP3A4 (0.51) MAPK14PDE5APDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK PTPN1 3316/4885GPR132 2062/4885MAPK14 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.